A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Required: FAP expression (clinical or imaging evidence per local assessment)

Must have received: systemic therapy — locally advanced unresectable or metastatic disease

Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.

Must have received: systemic therapy — advanced or metastatic disease

HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.

Must have received: HER2-targeted therapy — metastatic disease

HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).

Must have received: systemic therapy — metastatic disease

TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.

Must have received: platinum-based chemotherapy — platinum-resistant or refractory ovarian cancer

Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.

Must have received: systemic therapy — advanced or metastatic disease

Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.

Must have received: systemic therapy — advanced or metastatic solid tumors

Phase 1b: Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.

Cannot have received: adoptive T-cell therapy (CAR-T cell therapy, T-cell receptor (TCR) therapy)

Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T therapy, T-cell receptor [TCR] therapy, etc.])

Cannot have received: radiation therapy

Had previous hemi- or total-body radiation